
Keywords: 2G, second-generation; CML, chronic myelogenous leukemia; CP, chronic phase; CrI, credible interval; CCyR, complete cytogenetic response; MCyR, major cytogenetic response; R/I, resistant/intolerant; TKI, tyrosine kinase inhibitorCML; Ponatinib; Second-gen